LSE:AZNPharmaceuticals
AstraZeneca Oncology Outlook Shifts With New CALQUENCE And ENHERTU Milestones
AstraZeneca's CALQUENCE received FDA approval as the first all oral, fixed duration regimen for chronic lymphocytic leukemia and small lymphocytic lymphoma.
The EMA validated AstraZeneca's application for ENHERTU as a monotherapy for HER2 positive breast cancer after neoadjuvant therapy.
These regulatory milestones expand AstraZeneca's oncology treatment options for blood cancers and breast cancer.
AstraZeneca (LSE:AZN) is adding fresh regulatory momentum to an established oncology...